Filing Flows › Biomerica (BMRA) › Q4 FY26 › vs Q3 FY26
Biomerica (BMRA) Q4 FY26 vs Q3 FY26 (quarter over quarter)
Biomerica's revenue fell $112K (-11%) from $987K in Q3 FY26 to $875K in Q4 FY26. The biggest changes: Clinical Lab −$210K (-34%); Contract Manufacturing +$192K (+115%); Over-The-Counter −$95K (-48%).
Biomerica, Q4 FY26: revenue $875K (+17% year over year), operating margin -175.2%, net loss $1.1M, operating cash flow −$912K. The chart draws each line against Q3 FY26, the increases inside each band.
Every line
| Line | Q4 FY26 | Q3 FY26 | Change | % |
|---|---|---|---|---|
| Clinical Lab | $411K | $621K | −$210K | -34% |
| Contract Manufacturing | $359K | $167K | $192K | +115% |
| Over-The-Counter | $102K | $197K | −$95K | -48% |
| Physician’s office | $3K | $2K | $1K | +50% |
| Revenue | $875K | $987K | −$112K | -11% |
| Other income, net | $394K | −$6K | $400K | — |
| Net loss | $1.1M | $1.3M | −$167K | -13% |
| Costs & expenses | $2.4M | $2.3M | $115K | +5% |
| Operating costs | $2.4M | $2.3M | $123K | +5% |
| Income tax | $6K | $8K | −$2K | -25% |
| Cost of revenue | $946K | $1.0M | −$85K | -8% |
| Research & development | $205K | $178K | $27K | +15% |
| Sales & marketing | $381K | $415K | −$34K | -8% |
| General & admin | $876K | $661K | $215K | +33% |
| Operating cash sources | $1.1M | $1.3M | −$167K | -13% |
| Depreciation & amortization | $17K | $20K | −$3K | -15% |
| Share-based compensation | $91K | $135K | −$44K | -33% |
| Working capital & other | $125K | −$93K | $218K | — |
| Cash used in operations | $912K | $1.2M | −$338K | -27% |
| Net loss absorbed | $1.1M | $1.3M | −$167K | -13% |
Questions
How much did Biomerica's revenue grow quarter over quarter in Q4 FY26?
Biomerica's revenue fell $112K (-11%) from $987K in Q3 FY26 to $875K in Q4 FY26.
What drove Biomerica's revenue change in Q4 FY26?
Clinical Lab −$210K (-34%); Contract Manufacturing +$192K (+115%); Over-The-Counter −$95K (-48%).